TAF2 Drives Hepatocyte Survival in HCC: Hepatology March 26

Chromosome 8q amplification, a common genomic alteration in hepatocellular carcinoma (HCC), includes the gene TATA-box binding protein–associated factor 2 (TAF2), a key component of the TFIID basal transcription complex. This study demonstrates that TAF2 is overexpressed in human HCC tissues and cell lines, and higher expression correlates with poorer overall survival.

Using hepatocyte-specific TAF2 knockout mice, investigators showed that loss of TAF2 leads to hepatocyte death, compensatory proliferation, inflammation, and fibrosis, creating a microenvironment favorable for tumor development. Consequently, DEN/high-fat high-sugar diet–induced HCC was markedly increased in TAF2-deficient mice.

Conversely, TAF2 overexpression alone did not initiate liver tumors, but significantly enhanced MYC-driven hepatocarcinogenesis, suggesting that TAF2 acts as a tumor promoter rather than a primary oncogenic driver.

Mechanistically, TAF2 binds promoter regions of tumor-promoting genes and non-coding RNAs, enhancing transcription programs that support cancer hallmarks such as proliferation and survival.

Key Message:

TAF2 plays a central role in maintaining hepatocyte viability and can accelerate hepatocarcinogenesis in the presence of oncogenic signals, highlighting it as a potential biomarker and therapeutic target in HCC.